Doctours
A medical tourism marketplace helping Americans find, compare, book, and pay for vetted medical procedures abroad or within the US.
Website: https://www.doctours.com/
Cover Block
Publicly reported
| Attribute | Value |
|---|---|
| Name | Doctours |
| Tagline | A medical tourism marketplace helping Americans find, compare, book, and pay for vetted medical procedures abroad or within the US. |
| Stage | Pre-Seed |
| Business Model | Marketplace |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | Pre-seed |
Links
Publicly reported
- Website: https://www.doctours.com
- LinkedIn: https://www.linkedin.com/company/doctours
Summary and Signal
Publicly reported Doctours is a medical tourism marketplace attempting to bring structure and trust to a historically opaque and fragmented cross-border healthcare sector for American patients. The company's current pitch focuses on elective procedures like hair transplants, offering vetted, all-inclusive packages with transparent USD pricing and financing, which it claims can deliver 50 to 70 percent savings compared to US clinics [Doctours blog]. The operational wedge is a claimed patient-centric model that includes in-person clinic audits, surgeon license verification, and structured US-based aftercare with medical evacuation coverage [Doctours blog].
Leadership appears to have transitioned from founder Katelyn O'Shaughnessy, a Forbes 30 Under 30 travel entrepreneur whose prior startup was acquired, to a team led by engineer Girum Tihtina alongside co-founders Maurice Landers and Tillman Degens [TechCrunch, Jul 2019] [SpeakInOut Weekly News, Dec 2024] [The Pitch, Oct 2025]. The company's funding status is based on founder testimony from late 2025, stating a $1M pre-seed target with $850k committed and SAFEs offered at $8M and $10M post-money valuations, though this has not been independently verified [The Pitch, Oct 2025]. The business model is a classic marketplace, free for patients with clinics paying for coordination.
Over the next 12-18 months, the key watchpoints are the independent confirmation of the pre-seed round's closure and investor syndicate, the validation of its clinic audit and patient review claims through third-party channels, and its ability to expand beyond the initial hair transplant wedge into other elective procedures as indicated in earlier company descriptions [TechCrunch, Jul 2019].
Thinly sourced -- Founder claims on funding and metrics are unverified; team composition and product description are partially corroborated by multiple sources.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | Marketplace |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Pre-seed |
Company Overview
Publicly reported
The founding narrative for Doctours is split across two distinct time periods, with a leadership transition that is visible in public records but not formally detailed. The earliest public record of the company is a July 2019 TechCrunch article that described Doctours as "founded by serial travel entrepreneur Katelyn O’Shaughnessy, whose last company TripScope was acquired by Travefy" [TechCrunch, Jul 2019]. O’Shaughnessy was identified as the CEO and founder at that time and had been featured on Forbes’ 2016 30 Under 30 list [Medical Travel Today, Aug 2019]. This initial version of the company raised a $1.5 million round to build a platform for booking medical and dental treatments abroad [TechCrunch, Jul 2019].
By late 2024, public references to the founding team had changed. A December 2024 article reported that three cofounders,Maurice Landers, Girum Tihtina, and Tillman Degens,had relocated to Huntsville, Alabama under a state grant program [SpeakInOut Weekly News, Dec 2024]. In a podcast recorded in October 2025, Girum Tihtina was introduced as the founder and CEO of Doctours, an engineer who had spent years building international payment systems [The Pitch, Oct 2025]. The company’s headquarters location is not publicly available in any of the cited sources.
Key milestones are primarily self-reported via the company’s blog. As of August 2026, the company claimed to have 15 in-person-audited clinics and 387 verified patient reviews averaging 4.6 stars [Doctours blog, Aug 2026]. The blog also states the platform offers locked USD packages ranging from $2,200 to $8,690 [Doctours blog, Aug 2026]. The most recent funding activity is based on founder testimony from the October 2025 podcast, which described an ongoing pre-seed raise [The Pitch, Oct 2025]. There is no independent public confirmation of a round closure, investor participation, or a finalized cap table.
One source, partially checked -- Founders and early funding confirmed by 2019 press. Current team and claimed metrics are from company blog and founder interview; no independent verification of round closure or operational scale.
The Product and the Stack
MIXED The core product is a curated marketplace designed to de-risk the complex logistics of medical travel for American patients. Doctours positions itself not as a generic medical tourism portal, but as a full-service facilitator, or 'doctouring' service, that handles vetting, transparent pricing, travel coordination, and structured aftercare [Doctours blog]. The operational wedge is a claim of rigorous, patient-aligned vetting: the company states it conducts in-person audits of each clinic, verifies surgeon licenses with national authorities, and refuses kickbacks or paid placement [Doctours blog]. This is presented as a direct contrast to the less structured, often opaque nature of traditional medical tourism.
Patient-facing features center on search, comparison, and booking for elective procedures. The most detailed public information focuses on hair transplants, with all-inclusive package pricing presented in locked US dollars. According to company blog posts, packages for procedures abroad range from $2,200 to $8,690, with country-specific starting prices cited at $2,500 for Turkey and Mexico, $5,500 for Poland, and $7,000 for US-based options [Doctours blog]. The platform is free for patients, with clinics paying a coordination fee; patients can place deposits from $300 and access financing for up to 36 months [Doctours blog]. Post-procedure, Doctours claims to provide a US-based care team offering 12 to 36 months of structured follow-up, with medical evacuation and complication coverage built into bookings [Doctours blog].
The underlying technology stack is not detailed in public materials. The platform's functionality, as described, suggests a multi-sided marketplace software layer for clinic listings, patient profiles, booking, and payment processing. A significant inferred component is the international payment and currency exchange system required to offer locked USD pricing from foreign clinics, a complexity founder Girum Tihtina's background in building international payment systems is noted to address [The Pitch, Oct 2025]. There is no public roadmap for new technological features or stack evolution.
Thinly sourced, Product claims and metrics are sourced exclusively from the company's own blog and a founder podcast interview, with no independent third-party verification.
The Market They Are Entering
Publicly reported The structural mismatch between US healthcare costs and elective procedure demand is creating a durable, if fragmented, market for cross-border care, a dynamic Doctours aims to formalize.
Third-party market sizing for the specific medical tourism segment is not available in the captured sources. However, the company's own blog posts frame the opportunity by comparing US domestic prices for elective procedures against international alternatives. For hair transplants, the cited US price range is $10,000 to $15,000, while packages through Doctours' network abroad are listed from $2,200 to $4,000, representing savings of 50 to 70 percent [Doctours blog]. This price arbitrage is the primary demand driver, targeting American patients for whom such procedures are often excluded from insurance coverage. The company's focus extends beyond hair transplants to include cosmetic surgery, dental work, and other treatments, suggesting a broader addressable market within elective care [TechCrunch, Jul 2019].
Demand tailwinds are implied rather than explicitly cited by independent research. The company's content emphasizes factors like rising US healthcare costs, increased consumer comfort with international travel for services, and a growing awareness of medical tourism as an option [Doctours blog]. A key adjacent market is the domestic US market for cosmetic and elective procedures, which represents the high-cost alternative. Substitute markets include direct-to-clinic booking via online research, traditional medical tourism agencies, and domestic medical financing platforms that keep patients within the US system.
Regulatory and macro forces present both a risk and a potential moat. The company claims its operational model, dubbed "doctouring," is designed to comply with CDC guidelines for medical tourism, incorporating structured follow-up and medical evacuation coverage [Doctours blog]. Macro factors such as currency exchange rates, political stability in destination countries, and international travel accessibility directly impact service delivery and cost consistency. The lack of a centralized regulatory framework for international medical care places a premium on the vetting and safety assurances Doctours promises to provide.
US Hair Transplant | 10000 | USD
Turkey/Mexico via Doctours | 2500 | USD
Poland via Doctours | 5500 | USD
US via Doctours | 7000 | USD
The price ladder illustrates the core value proposition: anchoring against US domestic prices creates a clear savings narrative, while tiered international options allow for patient choice based on destination preference and budget. The spread between the highest international price ($5,500 for Poland) and the lowest US price ($7,000 via Doctours) is notably narrow, potentially positioning the company's US network as a premium-convenience option within its own marketplace.
One source, partially checked -- Pricing and savings claims are sourced solely from company blog posts; the US domestic price comparison aligns with general industry understanding but lacks independent third-party citation.
The Competitive Field
Public record plus analysis Doctours operates in a fragmented market where its primary competition is not a single, direct platform but a collection of uncoordinated alternatives, from traditional medical tourism agencies to direct clinic bookings and domestic care substitutes.
Given the absence of named, direct competitors in the structured sources, a detailed comparison table cannot be constructed. The competitive analysis proceeds based on the market map inferred from the company's own positioning against these broader alternatives.
The competitive map can be segmented into three layers. First, traditional medical tourism agencies and facilitators represent the incumbent model. These are typically regional operators or clinic-specific referral services that bundle travel logistics with procedure booking. Their advantage is local market knowledge and established clinic relationships, but they often lack the standardized vetting, transparent USD pricing, and structured US-based aftercare that Doctours claims as its wedge. Second, direct-to-clinic bookings enabled by clinic marketing and patient forums constitute a significant volume. This channel offers patients the illusion of cost control but places the entire burden of vetting, coordination, and post-operative support on the individual. Third, domestic care substitutes include US-based clinics offering financing or lower-cost domestic options, competing on convenience and perceived safety rather than price.
Where Doctours attempts to carve a defensible edge is through its claimed operational rigor and patient-centric model. The company's public materials emphasize in-person clinic audits, verification of surgeon licenses, and built-in medical evacuation coverage [Doctours blog]. This is paired with a business model assertion that it "answers to patients, not clinics" and refuses kickbacks [Doctours blog]. If executed consistently, this combination of rigorous supply-side vetting and aligned incentives could create a trust-based moat. However, this edge is highly perishable; it relies entirely on the company's capital and operational discipline to maintain audit standards as it scales. A single quality incident or a discovery of audit lapses would immediately erode this positioning.
The company's most significant exposure lies in distribution and brand recognition. It is attempting to build a two-sided marketplace in a category where supply (clinics) is globally dispersed and demand (patients) is geographically concentrated in the US but difficult to reach cost-effectively. Established travel platforms or large domestic healthcare providers could decide to layer a similar vetting and booking service atop their existing user bases, leveraging far greater traffic and trust. Furthermore, Doctours's current public focus on hair transplants, while a clear entry wedge, may limit its perceived scope and make it vulnerable to more specialized, single-procedure platforms that can achieve deeper domain expertise and supplier loyalty.
A plausible 18-month competitive scenario hinges on execution and capital. The winner in a scenario where patient trust becomes the paramount purchase driver would be the first platform to achieve critical mass of verified reviews and transparent outcomes data, likely whichever company secures the funding to aggressively scale its clinic network and consumer marketing. Conversely, the loser in a scenario where customer acquisition costs remain prohibitively high would be any capital-constrained marketplace that fails to achieve liquidity, becoming stuck with a small network that fails to meet patient search demands. Doctours's path depends on converting its claimed operational wedge into a scalable, defensible supply chain before larger adjacent players recognize the opportunity.
One source, partially checked -- Competitive analysis is inferred from the subject's own positioning statements and general market structure; no direct competitors are named in available sources.
Opportunity
Publicly reported The prize for Doctours is a position as the trusted, dominant intermediary in a multi-billion dollar cross-border elective healthcare market, capturing a share of the immense price arbitrage between US and international providers.
The headline opportunity is to become the category-defining platform for structured medical travel, akin to a Kayak or Airbnb for elective procedures. This outcome is reachable because the company's model directly addresses the core friction points that have historically plagued medical tourism: opaque quality, fragmented logistics, and financial risk. The cited evidence shows a deliberate wedge strategy, starting with a high-consideration, price-sensitive procedure like hair transplants [The Pitch, Oct 2025], and building a repeatable playbook for vetting, packaging, and financing that can be applied to adjacent categories like cosmetic surgery and dental work [TechCrunch, Jul 2019]. The company's claims of in-person audits and structured aftercare [Doctours blog] are the foundational elements of the trust required to move the category from a risky, self-directed search to a managed service, which is the prerequisite for scaling.
Multiple, specific growth paths exist beyond the initial wedge. The following scenarios outline plausible routes to significant scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Procedure Expansion | The company successfully replicates its hair transplant model into 2-3 adjacent high-margin elective categories (e.g., cosmetic dentistry, bariatric surgery). | Launch of a new, fully-packaged procedure vertical with dedicated clinic networks and marketing. | The platform's initial architecture is built for a broad procedure spectrum [TechCrunch, Jul 2019], and the operational model of vetting, packaging, and financing is procedure-agnostic. |
| Employer & Insurer Partnership | Doctours transitions from a direct-to-consumer marketplace to a B2B2C benefits provider, embedding its services into employer healthcare plans or supplemental insurance products. | Securing a pilot partnership with a self-insured employer or a regional health plan to offer medical travel as a covered benefit. | The company's emphasis on structured aftercare, complication coverage, and audit standards [Doctours blog] aligns with the risk-management needs of institutional payers seeking cost-containment solutions. |
| Geographic Network Dominance | The company achieves such density and reputation in a key destination country (e.g., Turkey for hair transplants) that it becomes the default channel for American patients, granting it superior economics and pricing power with clinics. | Reaching a critical mass of patient volume and reviews in a single country that significantly outpaces any single clinic's direct marketing efforts. | The company already reports concentrating its initial network in a handful of key countries [Doctours blog], and patient reviews are a central part of its trust-building [Doctours blog, Aug 2026]. |
What compounding looks like is a classic two-sided network effect reinforced by data. Each new patient booking generates a verified review and outcome data, improving the platform's ability to match future patients with the right clinics and procedures. This growing dataset enhances the value of the vetting and matching service for clinics, making the platform a more effective customer acquisition channel than their own marketing spend. For patients, a larger review corpus reduces perceived risk. The company's claim to "answer to patients, not clinics" and refuse kickbacks [Doctours blog] is a strategic bet that aligning incentives with the patient side will accelerate this flywheel, as trust becomes the primary defensible asset.
The size of the win can be framed by considering the total addressable savings the platform could intermediate. If the company captured even a single-digit percentage of the estimated annual outflow of US patients seeking elective procedures abroad,a market often cited in the tens of billions,its facilitated Gross Merchandise Value (GMV) would reach hundreds of millions. Taking a marketplace take-rate on that GMV, which the company's clinic-paid model implies, could support a valuation comparable to other specialized travel and healthcare marketplaces. For a concrete scenario, if the Procedure Expansion scenario plays out and Doctours becomes the leading platform for 3-4 major elective categories, a reasonable outcome could be a company valued on the order of several hundred million dollars, based on comparable transaction multiples in adjacent online health and travel services (scenario, not a forecast).
One source, partially checked -- Opportunity analysis is based on company-stated strategy and model from its blog and founder interviews; market size and comparable valuation context are not independently sourced from third-party research.
Sources
Publicly reported
[The Pitch, Oct 2025] Doctours: VC Funded Hair Transplants?! | https://www.gimletmedia.com/the-pitch/doctours-vc-funded-hair-transplants
[Doctours blog, Aug 2026] Doctours Blog | https://www.doctours.com/blog
[Doctours blog] Doctours Blog: Medical Tourism Explained for Beginners | https://www.doctours.com/blog/medical-tourism-explained-for-beginners
[TechCrunch, Jul 2019] Doctours raises $1.5M to help you book medical procedures abroad | https://techcrunch.com/2019/07/16/doctours-raises-1-5m-to-help-you-book-medical-procedures-abroad/
[SpeakInOut Weekly News, Dec 2024] Doctours Cofounders Relocate to Huntsville | https://speak-inout.com/doctours-cofounders-relocate-to-huntsville/
[Medical Travel Today, Aug 2019] Medical Travel Today Interview with Katelyn O’Shaughnessy | https://medicaltraveltoday.com/katelyn-oshaughnessy-ceo-founder-of-doctours/
[LinkedIn] Doctours LinkedIn Profile | https://www.linkedin.com/company/doctours
Articles about Doctours
- Doctours Vets 15 Clinics Abroad for the American Hair Transplant Patient — The medical tourism marketplace is betting that in-person audits and structured aftercare can build trust in a historically opaque category.